Drug Discovery Today
FEBRUARY 3, 2021
February 4th is World Cancer Day. As Covid continues to re-shape our lives it is important to keep awareness about men’s health high. Recent news about Greg Rutherford’s detection of a cyst is a reminder that it is important for men to get regular check-ups. Testicular cancer is one of the most common forms of cancer in males and it affects around 2,300 men in the UK each year.
Drug Patent Watch
OCTOBER 4, 2021
This is my talk from the 14th Annual Portfolio Planning and Partnership for Generic Conference. I discuss: Identifying generic entry opportunities at the earliest stages Discovering opportunities that avoid litigation…. The post Generic Portfolio Management, Partnering with Brands, and Staying Competitive appeared first on DrugPatentWatch - Make Better Decisions.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Eye on FDA
AUGUST 4, 2021
As more drugs are being approved, is FDA getting less advice than in the past? FDA maintains a vast network of outside advisors to provide input and counsel to the agency related to decisions on policy as well as product approvals. There are 31 advisory committees on matters ranging from food to medical devices to pediatric care. Within those focused on human drugs , there are 17 committees organized under therapeutic categories (Arthritis, Cardiovascular and Renal, Gastrointestinal, e.g.).
Drug Channels
NOVEMBER 2, 2021
Open enrollment is under way for the 2022 Medicare Part D plans. Our exclusive analysis of Center for Medicare & Medicaid Services’ (CMS) data reveals that preferred cost sharing pharmacy networks will maintain their dominance as an established component of Part D benefit design. For 2022: 98% of stand-alone Medicare Part D prescription drug plans (PDP) will have a preferred network. 66% of Medicare Advantage prescription drug (MA-PD) plans will have a preferred network.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
The Pharma Data
MARCH 8, 2021
Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics, LP today announced preliminary results from Ridgeback’s Phase 2a randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability, and efficacy to eliminate SARS-CoV-2 viral RNA of molnupiravir (EIDD-2801/MK-4482), an investigational oral antiviral agent.
Drug Discovery Today
SEPTEMBER 16, 2021
A drug already used to treat high blood pressure could be re-purposed as the first treatment to tackle a type of vascular dementia caused by damaged and ‘leaky’ small blood vessels in the brain, according to research part-funded by the British Heart Foundation and published today in the Journal of Clinical Investigation.
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
Drug Discovery Today
MARCH 26, 2021
Infex Therapeutics has filed for a UK patent for a novel therapy designed to tackle all coronavirus strains.
Drug Patent Watch
AUGUST 16, 2021
I’ll be leading a workshop on generic portfolio management, and also giving a talk, at the 14th annual Marcus Evans event on Portfolio Planning and Partnerships for Generics. The event…. The post Upcoming workshop on generic portfolio management appeared first on DrugPatentWatch - Make Better Decisions.
Eye on FDA
JULY 29, 2021
In the face of a crisis situation, it is a given that the clarity and thoroughness of the communications response is key to resolving the issue and mitigating any reputational damage. Perhaps no other decision by the Food and Drug Administration has garnered as much controversy, as the recent one to authorize the accelerated approval a new treatment for Alzheimer’s.
Drug Patent Watch
AUGUST 23, 2021
Annual Drug Patent Expirations for JARDIANCE Jardiance is a drug marketed by Boehringer Ingelheim and is included in one NDA. It is available from four suppliers. There are six patents…. The post New patent for Boehringer Ingelheim drug JARDIANCE appeared first on DrugPatentWatch - Make Better Decisions.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Drug Patent Watch
AUGUST 14, 2021
Annual Drug Patent Expirations for GLYXAMBI Glyxambi is a drug marketed by Boehringer Ingelheim and is included in one NDA. It is available from one supplier. There are eleven patents…. The post New patent for Boehringer Ingelheim drug GLYXAMBI appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
AUGUST 24, 2021
Annual Drug Patent Expirations for SYNJARDY Synjardy is a drug marketed by Boehringer Ingelheim and is included in two NDAs. It is available from one supplier. There are six patents…. The post New patent for Boehringer Ingelheim drug SYNJARDY appeared first on DrugPatentWatch - Make Better Decisions.
Eye on FDA
AUGUST 13, 2021
What does “fully vaccinated” mean today? In the face of the widening spread of the SARS-Cov-2 variant, the rise in breakthrough cases, and data that suggests a slight waning effect over time of vaccines, FDA acted yesterday to protect some of the most vulnerable by amending the Emergency Use Authorization of the mRNA vaccines. People who have had organ transplants and people who are immunocompromised may now get a third dose.
Drug Patent Watch
JULY 25, 2021
This chart shows the pharmaceutical companies with the most ointment dosed drugs. For a different perspective, see the most popular dosage types. The companies with the most ointment dosed drugs…. The post Which pharmaceutical companies have the most ointment dosed drugs? appeared first on DrugPatentWatch - Make Better Decisions.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Drug Patent Watch
JULY 9, 2021
This chart shows the pharmaceutical companies with the most patents in Poland. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Poland? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JULY 22, 2021
Annual Drug Patent Expirations for LENVIMA Lenvima is a drug marketed by Eisai Inc and is included in one NDA. There are five patents protecting this drug and one Paragraph…. The post New patent for Eisai Inc drug LENVIMA appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JULY 7, 2021
Annual Drug Patent Expirations for XHANCE Xhance is a drug marketed by Optinose Us Inc and is included in one NDA. There are thirteen patents protecting this drug. XHANCE drug…. The post New patent for Optinose Us drug XHANCE appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JUNE 18, 2021
Annual Drug Patent Expirations for CLARINEX Clarinex is a drug marketed by Merck Sharp Dohme and is included in five NDAs. It is available from two suppliers. There are four…. The post New patent expiration for Merck Sharp drug CLARINEX appeared first on DrugPatentWatch - Make Better Decisions.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Drug Patent Watch
AUGUST 6, 2021
This chart shows the pharmaceutical companies with the most patents in Bulgaria. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Bulgaria? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JUNE 4, 2021
Annual Drug Patent Expirations for VELPHORO Velphoro is a drug marketed by Vifor Fresenius and is included in one NDA. It is available from one supplier. There are seven patents…. The post New patent for Vifor Fresenius drug VELPHORO appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JUNE 7, 2021
Annual Drug Patent Expirations for TOVIAZ Toviaz is a drug marketed by Pfizer and is included in one NDA. It is available from two suppliers. There are four patents protecting…. The post New patent for Pfizer drug TOVIAZ appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JULY 26, 2021
This chart shows the generic pharmaceutical companies that had the most successful drug patent challenges from 2016 to 2021. Companies that successfully challenge patents on branded drugs are granted six…. The post Most prolific drug patent challengers appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
MAY 31, 2021
This chart shows the pharmaceutical companies with the most suspension dosed drugs. For a different perspective, see the most popular dosage types. The companies with the most suspension dosed drugs…. The post Which pharmaceutical companies have the most suspension dosed drugs? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JUNE 6, 2021
This chart shows the drugs with the most patents in Russian Federation. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical drugs have the most drug patents in Russian Federation? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JUNE 4, 2021
Annual Drug Patent Expirations for VIBERZI Viberzi is a drug marketed by Allergan Holdings and is included in one NDA. It is available from one supplier. There are fourteen patents…. The post New patent for Allergan Holdings drug VIBERZI appeared first on DrugPatentWatch - Make Better Decisions.
Eye on FDA
MAY 21, 2021
Vaccination has been robust. Cities are opening up. Plans are underway for back-to-school. Travel is robust. Offices are cautiously re-opening. There are multiple hallmarks that, whatever the consequences, we are going back to normal. The age of COVID-19 will likely continue, but with the emergence of a significant proportion of the population with vaccines pumped into them, we headed back on almost every level.
Eye on FDA
MARCH 31, 2021
This week New York became the first state to make available a means for mobile digital confirmation that an individual has been vaccinated for COVID-19. Popularly known as “immunity passports” they are in fact more than that. The New York app, dubbed “Excelsior Pass” can also carry information regarding an person’s latest COVID-19 test result.
Drug Patent Watch
AUGUST 27, 2021
This chart shows the pharmaceutical companies with the most spray dosed drugs. For a different perspective, see the most popular dosage types. The companies with the most spray dosed drugs…. The post Which pharmaceutical companies have the most spray dosed drugs? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JULY 24, 2021
This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Slovakia. SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating…. The post Which pharmaceutical companies have the most SPCs in Slovakia? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
FEBRUARY 3, 2021
This article was originally published by Ioana Gherghescu and Begoña Delgado-Charro in Pharmaceutics 2021, 13(1) under a Creative Commons Attribution License. Abstract Biosimilar medicines expand the biotherapeutic market and improve…. The post The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JANUARY 20, 2021
This chart shows the drugs with the most patents in Singapore. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.…. The post Which pharmaceutical drugs have the most drug patents in Singapore? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JANUARY 31, 2021
This chart shows the pharmaceutical companies with the most patents in Slovenia. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Slovenia? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JUNE 12, 2021
This chart shows the drugs with the most patents in Chile. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.…. The post Which pharmaceutical drugs have the most drug patents in Chile? appeared first on DrugPatentWatch - Make Better Decisions.
Expert insights. Personalized for you.
201 
Let's personalize your content